The period of economic transition has had severe consequences for health and health systems in Ukraine. The tuberculosis (TB) situation illustrates this. The strategy recommended by the World Health Organization (WHO) for TB, directly observed treatment short-course (DOTS), has the potential to provide real improvements in TB services, forming the basis of the response to the growing epidemic. In 2002, Ukraine, financially supported by USAID and the European Community (EC), began to introduce DOTS through pilot projects in Mariupol and Kyiv City. The aim of this study is to assess the feasibility, effectiveness, health service cost, patient cost, and the cost-effectiveness of these pilots, in order to inform the national scale-up of DOTS.
Introduction
The period of economic transition in the Ukraine and other ex-Soviet countries has had severe consequences for tuberculosis (TB) control. TB control services have faced several major challenges. Firstly, TB services experienced a severe reduction in funding. Secondly, the population became substantially poorer. Thirdly, social security benefits for TB patients (disability pension, job security) have disappeared. Lastly, there has been a concurrent spread of the HIV/AIDS-epidemic, bringing with it more dually infected TB cases (Hamers and Downs 2003; Drobniewski et al. 2005) . As a result of these factors, TB case notification rates in Ukraine have more than doubled since the collapse of the Soviet Union, from 32 per 100 000 in 1990 to 80.9 per 100 000 in 2004. The incidence of multi-drug resistant TB (MDR-TB) has also risen (Dye et al. 2002) .
Although it is difficult to attribute the extent to which the epidemic has been affected by different factors, it is clear that the health system has failed to respond (Coker et al. 2004) . The system for controlling TB in Ukraine was established in the time of the Soviet Union. Although general health services have the ability to diagnose TB, many cases are detected through mass screening of the population by fluorography. TB services are vertically organized and highly centralized. General health services have no major role in treating TB patients. TB patients typically undergo lengthy, non-standardized treatments, in specialized TB hospitals. The infrastructure of these specialized services has deteriorated and staff morale has been substantially weakened by low salaries and reduced professional status. It is argued that a combination of administrative inertia, professional beliefs about communicable disease control and scepticism about the evidence base for directly observed treatment short-course (DOTS) (WHO 1999) have prevented the adoption of internationally accepted best-practice (Coker et al. 2004) .
Since 2002, the World Health Organization (WHO), USAID, the European Union (EU) and KNCV Tuberculosis Foundation have worked together, implementing pilot projects introducing DOTS. The aim of these pilots has been: (') gradual reorientation of TB detection to passive screening using microscopy; (b) standardization of treatment regimens; (c) increased use of ambulatory treatment; (d) increased involvement of general health services in case detection and treatment. The aim of this paper is to report and assess the feasibility, effectiveness, and cost-effectiveness of these pilots and to inform the national level to scale-up DOTS.
Methods Setting
Two pilot projects were established in Mariupol and Kyiv City. Mariupol city has a population of half a million people. In 2003 the case notification rate was 87 per 100 000 and 445 new cases of TB were registered. Kyiv city has a population of 2.64 million. In 2001 the case notification rate was 40.5 per 100 000 and 1056 TB cases were newly registered.
Alternative TB control strategies A summary of the existing and piloted DOTS-based TB control strategies is presented in Table 1 . These differ from each other in several respects. Firstly, Ukraine has traditionally relied on mass fluorography screening to detect TB cases. In contrast the pilot projects introduced passive case-detection using sputum smear microscopy through general health services. Secondly, TB patients in Ukraine were previously treated using individualized treatment. This treatment required patients to stay between 6 months to 2 years in hospital (averaging in the pilot sites around 8 months). Treatment in both sites continued until the radiological closure of cavities, and patients could be monitored as outpatients for up to 10 years. In contrast, the pilot projects introduced short standardized treatment regimens. These shorter regimens consisted of two phases, an intensive phase and a continuation phase. The intensive phase used four drugs (H, R, Z and E or S) 1 for at least 2 months, followed by a 4-month continuation phase, using two drugs (H and R). During the intensive phase, patients were treated as inpatients in a TB hospital. During the continuation phase, patients could opt for ambulatory treatment, provided under direct observation (DOT) from TB dispensaries, polyclinics, or Red Cross facilities. A social support scheme for TB patients was set up to support adherence to treatment. The Red Cross provided basic food rations to all ambulatory patients every fortnight. Treatment success was monitored by sputum smear conversion, but also by culture and chest X-ray.
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Assessment of feasibility
The progress of the pilot projects was recorded using the WHO and EC's TACIS reporting system. Using a logical framework approach, this monitors progress against project results and project milestones. Key results included: general health services staff (GHS) able to correctly identify and manage suspects and to administer treatment on an ambulatory basis; WHO-recommended treatment schemes implemented; passive case finding (PCF) improved through promoting health-seeking 
Estimating effectiveness
Effectiveness was measured using a number of metrics, including measures of the effectiveness of case detection, measures of treatment success and measures of health outcome as outlined in the WHO guidelines (WHO 1997) . Ideally, comparing the effectiveness of two TB control strategies should be done through a randomized controlled trial. However, this was not possible, as the projects were primarily aimed at demonstrating the feasibility of DOTS, not as a controlled trial of its effectiveness. Therefore, the method used to assess effectiveness was a 'before and after' approach. Data on the effectiveness of mass screening by fluorography were collected retrospectively, from the existing case-notification system. Data on smear microscopy were collected using a recording and reporting system established during the pilot projects based on WHO guidelines (WHO 1997) . Effectiveness of treatment was measured using WHO-defined treatment success of new smear-positive TB cases (WHO 1997). 3 Treatment success could be measured in Mariupol, but in Kyiv it was not possible to measure outcomes at the end of treatment. This was only possible at the point of 2 months, due to the length of available funding. Effectiveness of the previous system of treatment was measured retrospectively using medical records. An algorithm to obtain comparable indicators of treatment success was developed using test results and patient events to determine cure or treatment completion at 8 months (the time horizon for DOTS) for all bacteriologically confirmed TB cases. It was not possible to exclude non-pulmonary respiratory TB from this effort. However, these cases are unlikely to have bacteriological confirmation, so outcomes for respiratory and pulmonary TB are regarded as broadly comparable. 4 It was also not possible to exclude patients who were culture positive but smear negative in the old reporting system. These patients are also likely to have better treatment outcomes than those who are smear positive as they have a less severe form of the disease. Finally deaths averted and disability-adjusted life years (DALYs) gained were estimated using international life expectancies in accordance with WHO guidelines (Tan-Torres Edejer et al. 2003). These estimates were based on treatment outcome at 8 months. They did not include the DALYs gained from reductions in transmission.
Estimation of health service costs
Health service costs were estimated using an 'ingredients approach'. This method measures the quantities of all resources used and prices/values them to arrive at cost (Tan-Torres Edejer et al. 2003 ). An exception was made for overhead costs for both inpatient and outpatient days. These were estimated using standard methods, collecting overhead expenditure data and allocating to TB control activities using the step-down method (Drummond et al. 1997) . Data were sourced from one TB hospital in Mariupol and four TB hospitals in Kyiv City, ranging in size from 100-400 beds. Data were also collected from six GHS polyclinics. Polyclinics were selected using stratified sampling, dependant on area and utilization, from 60 polyclinics in Kyiv City. Fluorography costs were estimated using expenditure data from the Central TB Services. We attributed all expenditure on fluorography to TB services. Although fluorography may detect a variety of other lung diseases, in Ukraine it is primarily funded on the basis of its role in detecting TB cases.
The average cost of diagnosis and treatment was calculated by using the average number of outpatient visits, inpatients bed-days, drug costs and diagnostic costs for different types of patients (Floyd 2002) . Activity data were sourced retrospectively from hospital and TB services' medical records and patient records databases.
Estimating patient costs
Data on patient costs were collected in 2004 from Kyiv and Mariupol using a structured questionnaire. The questionnaire was also used for a study on health-care-seeking behaviour (Van der Werf et al. 2006) . Data were collected on direct and indirect costs of both patients and care-givers. Information for each patient was gathered from medical records and by face-toface interview. All patients over 15 years of age who consented to participate and were diagnosed with pulmonary TB less than 4 months before the interview (to reduce recall bias) were eligible for inclusion in the study. Patients not speaking Ukrainian or Russian, patients with a chronic underlying pulmonary condition and patients who were seriously ill were excluded from the study. The number of TB patients selected per facility was proportional to the number of new patients admitted to the facility in 2002. To estimate the cost of ambulatory care, we interviewed patients attending Red Cross sites in Kyiv City, as insufficient numbers of patients were being treated in general health services at the time. The data were entered in Microsoft Access in duplicate by two different persons and the two files were compared to identify typing errors. Analysis was conducted using SPSS.
For all local costs we use an exchange rate of 5.31 UAH to 1 US$ (International Monetary Fund). Costs are presented in exchange rate US$ constant prices for 2003. We used a discount rate of 5% when annuitizing capital costs (Walker and Kumaranayake 2002) . When comparing costs between time periods, we used a 5% deflator.
Assessment of cost-effectiveness
Cost-effectiveness was assessed using standard methods and taking a societal perspective (Drummond et al. 1997; Floyd 2002) . A sensitivity analysis was conducted on the impact on our results of changing several variables. These included activity levels (i.e. number of outpatient visits, inpatient bed-days), to assess the effects of uncertainty surrounding retrospective data collection; and effectiveness, to assess the effects of uncertainty surrounding the quality of medical records. All spreadsheets on costs, effectiveness and cost-effectiveness estimates are available from the corresponding author.
Results
Feasibility
The pilot projects were partially successful in achieving their results. The projects successfully provided the resources, systems and training to establish a functioning DOTS-based TB control system. Smear microscopy was introduced in GHS, standardized treatment regimens were provided, and patients had (and used) the option to receive the continuation phase of treatment on an ambulatory basis.
However, the pilots were not fully able to replace the existing system with DOTS. Fluorography screening continued during both pilot projects. It was only at the end of the pilot project in Mariupol that restricting the use of fluorography screening to high-risk groups was adopted. In Kyiv, TB specialists agreed to the WHO-recommended schemes as the minimum requirement, but felt it necessary to retain the flexibility to treat certain patients in an individualized way. TB doctors were therefore allowed to continue treatment for longer if they felt this was necessary. A further compromise was reached in Kyiv whereby drug susceptibility testing (DST) testing was then carried out on all new TB cases. Once the result was known, in case of drug resistance a new treatment regimen with second line anti-TB drugs was initiated. This individualized treatment had to be approved by the 'Central Physician Consultation Committee', a committee of TB specialists that met on a weekly basis and evaluated all newly registered TB cases. Finally, neither pilot project managed to reduce the level of follow-up treatment (post 8 months) even in cases that had a confirmed cure.
Effectiveness
Both projects were successful in demonstrating improvements in TB treatment effectiveness. Table 2 shows effectiveness of TB treatment before and during the pilot projects. In Mariupol, the treatment success rate increased rapidly between 2001 and 2003, with the introduction of the short-course WHO regimen. Failures and death rates fell, but the most dramatic change was a reduction in the numbers for treatment interrupted. In Kyiv, data for the first cohort of patients were not available at the end of the pilot project. Initial sputum results after 2 months showed 63% of patients converting to negative. There was a 43% treatment success rate in the old system, suggesting that improvements were made.
Health service costs
Both projects also demonstrated a reduction in costs. Tables 3  and 4 show the health service costs for each alternative for each city. In Kyiv, the average health service cost of treating and diagnosing a case of smear-positive TB in the old system was $1141 and in Mariupol $951. This is slightly lower than the costs found in Russia (Migliori et al. 1998; Jacobs et al. 2002) . By comparison, the cost of diagnosis and treatment during the projects was found to be substantially lower, at $663 for Mariupol and $589 for Kyiv. The reduction in cost is primarily due to the shortened length of inpatient stay. Drug costs were not substantially reduced in Mariupol remaining at around $90-100 per patient. Moving to internationally purchased WHO regimens would further reduce costs to around $20. However, it should be noted that outpatient visit costs in the polyclinics were found to be higher than at hospital. This is because polyclinic capacity was underutilized and may change as more cases are treated on an ambulatory basis.
Patient costs
The impact of the pilot projects on patient costs was mixed. In Kyiv and Mariupol, 156 and 58 new smear-positive TB (Smþ PTB) cases being treated as inpatients, and 51 and 50 outpatients, were interviewed, respectively. An additional 36 polyclinic patients receiving outpatient care from Red Cross facilities were also interviewed in Kyiv. Tables 5 and 6 present the results. Where the cost is indicated as negative, this means that patients benefited from treatment, as the social benefits they received outweighed the costs. In Mariupol, on average, patients receiving TB treatment in both 2001 and 2003 benefited economically. In Kyiv, on average, inpatients treated in 2003 incurred a cost, despite the social benefits available, as both patients and caregivers experience substantial income losses. 
Cost-effectiveness
Both projects demonstrated improvements in cost-effectiveness. Tables 7 and 8 present the results on cost-effectiveness. Our findings show that the cost of detecting one case of TB using mass screening is between $5713-10 229 per case detected. By comparison it costs between $188-247 to detect a case using passive case detection. The cost-effectiveness of diagnosis and treatment improved in both settings between 2001 and 2003. In Mariupol, the cost per case cured fell from $2729 to $1333, more than a 50% reduction. In Kyiv, the fall was equally dramatic, with falls from $6504 to $2414 (assuming a 63% eventual cure rate). 5 The cost per DALY for the new method ranges from $55 to $100. Our sensitivity analysis showed that these results are robust after adjusting for reasonable ranges of activity rates and effectiveness.
Discussion
The pilot projects demonstrate that DOTS is potentially effective and cost-effective in Ukraine. This mirrors findings from other evaluations of DOTS pilots from the ex-Soviet Union (Migliori et al. 1998; Jacobs et al. 2002) . The improvement in costeffectiveness is due to a number of factors. Firstly, fluorography has a substantial cost and may not be as effective as passive case-detection using microscopy. In Kyiv city, with a population of 2.64 million, almost half of the population is screened by fluorography every year. To detect one case, more than 2500 people needed to be screened. Despite this substantial effort, in the year 2000, only 30% of all new cases were detected through fluorography. However, fluorography consumes around 50% of the total budget available for TB control. Secondly, the introduction of standardized treatment regimens substantially reduces costs, without a substantial impact on effectiveness. In 2000, the estimated budget requirement for TB drugs for new patients (WHO category I) for Kyiv City was $207 659. Yet the total number of new TB cases diagnosed annually is around 1000 and a full course of the WHOrecommended category I treatment regimen can be purchased for as little as $20 through international non-profit suppliers. The Mariupol pilot found that despite relatively high failure rates and the threat from MDR-TB, standardized short-course Passive case detection using microscopy 3.50 70.6 247
Kyiv City Active case detection using fluorography screening 3.67 2787 10 229
Passive case detection using microscopy 3.96 47.5 188 Ã Excluding transmission effects, with an assumption of 20% self cure and assumption that 90% of those cured would otherwise die.
regimens are effective for the majority of TB patients. Finally, the pilots demonstrated that ambulatory treatment is potentially feasible, less costly and does not reduce the effectiveness of treatment. In Mariupol, ambulatory treatment substantially improved adherence to treatment and therefore its effectiveness. Despite these clear findings, it should be noted that these pilots were primarily designed as implementation pilots and therefore our analysis of cost-effectiveness has several limitations. Firstly, the weakness of a 'before and after' design is clearly illustrated by the increase in patient costs after DOTS in Kyiv. This increase is primarily explained by the high incomes of the group of patients opting for ambulatory care. A further example is the difference between the definition of patients (i.e. the definition of respiratory TB and inclusion of smear-negative TB) when comparing treatment effectiveness between the pilots and the old system. In addition, as fluorography continued throughout the project period, it is likely that the effectiveness of passive detection through microscopy is also underestimated. However all these factors bias our analysis of cost-effectiveness towards the old system, and therefore our central finding that the pilots were more cost-effective remains robust. Lastly, it should be noted that our analysis only shows results from pilots over a short period. Particularly in the case of results from Kyiv, our results are only suggestive regarding treatment success.
Despite these weaknesses, the pilots demonstrate the potential effectiveness and cost-effectiveness of DOTS in Ukraine. However, they did not manage to fully introduce DOTS and replace the ex-Soviet approach. This indicates that considerable effort may still be required before DOTS can be implemented as a national TB control strategy. The pilot projects suggest a number of issues that need to be tackled. Firstly, there remains considerable concern among TB specialists that some high-risk groups will not be identified by passive case detection, and therefore resistance to removing mass screening remains. A solution would be to retain screening for high-risk groups. Further study is therefore recommended to better identify which groups are at a high risk of TB in Ukraine.
Secondly, the use of microscopy as a fast, easy and cheap method to identify infectious cases was accepted only reluctantly. It was seen as an old methodology, not relevant for the needs of Ukraine. Yet it allows early segregation of infectious patients and therefore is important in the reduction of nosocomial transmission and prevention of occupational risk of infection for the staff. Its usefulness in this role needs to be further stressed in the Ukrainian adapted WHO guidelines.
Lastly, there is still some way to go in convincing TB specialists that standardized treatment should replace individualized treatment in a context where there is a threat from MDR-TB. The pilot projects improved the process for providing individual treatment, but did not remove it. Treatment failure rate in the Mariupol pilot remained high at 14%, and was of considerable concern to TB specialists. In Kyiv, TB specialists were only prepared to accept DOTS on the basis that DST would be carried out on all positive cases beginning treatment. Knowledge is scarce on the threat of man-made resistance by prescribing insufficient doses or too few combinations of effective drugs. Further studies are therefore recommended to investigate the best method for addressing the problem of treatment failures within the Ukraine. A clear policy for the identification and treatment of MDR-TB needs to be established that adequately addresses Ukrainian TB specialists concerns about the spread of the disease.
When the project started, TB specialists were collecting and aggregating a wealth of data, but not analysing the results in order to remedy weaknesses. Historically, weaknesses were hidden to avoid punishment by the administration. In the pilot sites the administration was change oriented, and the systematic analysis of effectiveness did create 'advocates' for the broad DOTS strategy. This in some part led to the adoption of DOTS as a national TB control strategy in 2005. However, even if the remaining evidence gaps are addressed, our analysis of costs also shows that there are significant economic disincentives that may affect the scale-up of DOTS in Ukraine.
The introduction of DOTS affects both patients and providers economically. On the patient side, hospital admissions can fulfill a social purpose for some patients (Atun et al. 2005b) . This is particularly the case with the homeless, where TB hospitals provide beds and social support. However, contrary to widespread belief that high numbers of TB patients are homeless in Ukraine, this study found that only 5.3% of pulmonary TB patients in Kyiv are homeless. In fact, the patient costs survey shows that the majority of patients incur substantial costs with hospitalization. It is probable that this high opportunity cost of inpatient care is a major factor for defaulting. When the results of this study were presented to hospital managers and TB clinicians, most recognized this as the primary reason given for defaulting, reporting that most defaulters were those with higher incomes, who left hospital as soon as they felt well. In addition, the pilot in Kyiv demonstrates that for the minority of patients who benefit from hospitalization, some of these social benefits can be successfully delivered through an outpatient/community-based approach, supporting adherence. It therefore is feasible for TB services to link with other services to ensure that the minority who are in need of substantial economic support get the help they need. A hospital bed is unlikely to be the cheapest way of providing much needed accommodation.
The reduction in hospitalization resulting from increasing ambulatory treatment will have a significant impact on the funding of TB control providers. The short time frame of the project meant that the thorny issue of TB hospital down-sizing was not addressed. In fact the additional resources provided through pilot projects may mask any reductions in hospital incomes resulting from reductions in inpatient care. This issue will become apparent in a national scale-up. At present, there is a substantial economic incentive to maintain long lengths of stay as hospitals in Ukraine are paid according to the number of beds and norms for resource usage. Given the limited number of TB patients, hospitals need to keep patients in their beds in order to maintain the number of beds when reviews are made, and therefore maximize revenue. This provides a disincentive to down-size the number of hospital beds. Moving to a payment system where hospitals are paid a fixed fee per case would provide an incentive to treat patients in the lowest cost way, but this would need to be carefully introduced. Safeguards would need to be made to ensure that an adequate quality of care was provided and that no perverse incentives occur to over-diagnose cases. In addition, policymakers must develop a transparent pathway for down-sizing TB hospitals that includes adequate compensation for and the staff currently working in these hospitals. In Ukraine, the average age of TB clinicians in Kyiv is over retirement age, yet state pensions have been substantially reduced, removing any economic incentive to retire.
Attention also needs to be given to incentives provided to general health services. National scale-up will not be achieved if there is a disincentive to general practitioners to provide TB treatment. Little is known about the level of informal payments in Ukraine. However, anecdotal evidence suggests that they are significant. The patient cost study found low levels of informal payments to TB doctors. This supports the argument that newly trained doctors are reluctant to specialize in communicable diseases due to the low level of informal income associated with these diseases. Ensuring adequate payments to general practitioners providing 'free' TB services may therefore also facilitate reform.
Conclusion
This study shows that DOTS can improve TB control in Ukraine. This will enable Ukraine to combat the TB epidemic in a sustainable way. The DOTS-based approach is likely to both substantially increase the effectiveness of TB control and reduce the costs of TB diagnosis and treatment to the health service and the patient. However, in order to realize these gains, health systems planners now need to find ways of addressing both the evidence-based concerns of Ukrainian TB physicians, and economic incentives to both the users and the providers. These should be addressed as an essential part of the overall strategy for expanding DOTS in Ukraine.
